Prostate Cancer and Prostatic Diseases - Table of Contents alert Volume 15 Issue 1

TABLE OF CONTENTS Volume 15, Issue 1 (March 2012) In this issue Reviews Original Articles Also new AOP Sign up for e-alerts Recommend to your library Web feed Subscribe Advertisement Prostate Cancer and Prostatic Diseases covers all aspects of prostatic diseases, in particular prostate cancer. The journal is of interest to surgeons, oncologists, urologists, clinicians, and researchers involved in diseases of the prostate. It publishes original articles in basic and clinical research, reviews, topical comments, and critical appraisal of scientific meetings. Can’t access full-text articles from this alert? Let your librarian know you want full-text access from your desktop.   Reviews Top Overcoming the challenges of robot-assisted radical prostatectomy M A Goldstraw, B J Challacombe, K Patil, P Amoroso, P Dasgupta and R S Kirby Prostate Cancer Prostatic Dis 2012 15: 1-7; advance online publication, August 16, 2011; 10.1038/pcan.2011.37 Abstract | Full Text Original Articles Top Relationship between the localization of fibroblast growth factor 9 in prostate cancer cells and postoperative recurrence J Teishima, K Shoji, T Hayashi, K Miyamoto, S Ohara and A Matsubara Prostate Cancer Prostatic Dis 2012 15: 8-14; advance online publication, October 18, 2011; 10.1038/pcan.2011.48 Abstract | Full Text Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells S M Manohar, A A Padgaonkar, A Jalota-Badhwar, S V Rao and K S Joshi Prostate Cancer Prostatic Dis 2012 15: 15-27; advance online publication, November 15, 2011; 10.1038/pcan.2011.51 Abstract | Full Text Adiponectin inhibits oxidative stress in human prostate carcinoma cells J-P Lu, Z F Hou, W C Duivenvoorden, K Whelan, A Honig and J H Pinthus Prostate Cancer Prostatic Dis 2012 15: 28-35; advance online publication, January 17, 2012; 10.1038/pcan.2011.53 Abstract | Full Text Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis A Serpa Neto, M Tobias-Machado, M A P Esteves, M D Senra, M L Wroclawski, F L A Fonseca, R B dos Reis, A C L Pompeo and A D Giglio Prostate Cancer Prostatic Dis 2012 15: 36-44; advance online publication, September 6, 2011; 10.1038/pcan.2011.4 Abstract | Full Text 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature G Bauman, T Belhocine, M Kovacs, A Ward, M Beheshti and I Rachinsky Prostate Cancer Prostatic Dis 2012 15: 45-55; advance online publication, August 16, 2011; 10.1038/pcan.2011.35 Abstract | Full Text Clinicopathological predictors of systemic progression and prostate cancer mortality in patients with a positive surgical margin at radical prostatectomy S A Boorjian, M K Tollefson, L J Rangel, E J Bergstralh and R J Karnes Prostate Cancer Prostatic Dis 2012 15: 56-62; advance online publication, August 2, 2011; 10.1038/pcan.2011.36 Abstract | Full Text Construct validity in a high-fidelity prostate exam simulator C G Kowalik, G J Gerling, A J Lee, W C Carson, J Harper, C A Moskaluk and T L Krupski Prostate Cancer Prostatic Dis 2012 15: 63-69; advance online publication, August 23, 2011; 10.1038/pcan.2011.38 Abstract | Full Text The association of diabetes and positive prostate biopsy in a US veteran population K A Moses, O A Utuama, M Goodman and M M Issa Prostate Cancer Prostatic Dis 2012 15: 70-74; advance online publication, September 6, 2011; 10.1038/pcan.2011.40 Abstract | Full Text Impact of pretreatment factors, biopsy Gleason grade volume indices and post-treatment nadir PSA on overall survival in patients with metastatic prostate cancer treated with step-up hormonal therapy S Miyamoto, K Ito, M Miyakubo, R Suzuki, T Yamamoto, K Suzuki, K Suzuki and H Yamanaka Prostate Cancer Prostatic Dis 2012 15: 75-86; advance online publication, October 11, 2011; 10.1038/pcan.2011.47 Abstract | Full Text A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study J E Ward, T Karrison, G Chatta, M Hussain, D Shevrin, R Z Szmulewitz, P H O'Donnell, W M Stadler and E M Posadas Prostate Cancer Prostatic Dis 2012 15: 87-92; advance online publication, October 18, 2011; 10.1038/pcan.2011.49 Abstract | Full Text Efficacy and safety of leuprolide acetate 6-month depot for suppression of testosterone in patients with prostate cancer A Spitz, J M Young, L Larsen, C Mattia-Goldberg, J Donnelly and K Chwalisz Prostate Cancer Prostatic Dis 2012 15: 93-99; advance online publication, October 25, 2011; 10.1038/pcan.2011.50 Abstract | Full Text Utility of PCA3 in patients undergoing repeat biopsy for prostate cancer A K Wu, A C Reese, M R Cooperberg, N Sadetsky and K Shinohara Prostate Cancer Prostatic Dis 2012 15: 100-105; advance online publication, November 1, 2011; 10.1038/pcan.2011.52 Abstract | Full Text Cause-specific mortality following radical prostatectomy S Shikanov, M Kocherginsky, A L Shalhav and S E Eggener Prostate Cancer Prostatic Dis 2012 15: 106-110; advance online publication, November 15, 2011; 10.1038/pcan.2011.55 Abstract | Full Text Advertisement Why submit your paper to Prostate Cancer and Prostatic Diseases? Over 90,000 recipients will receive via e-mail a copy of the table of contents for the issue in which your article is published. There are an average of 30,000 page views across the Prostate Cancer and Prostatic Diseases web site per month. On average authors receive a first decision on their paper within 30 working days. Visit our Author page to learn about the benefits of publishing in the Journal and guidelines on how to submit your paper.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Prostate Cancer and Prostatic Diseases. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.